OncoMatch/Clinical Trials/NCT05879653
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Is NCT05879653 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including MK-3475 and ASG-22CE for bladder cancer.
Treatment: MK-3475 · ASG-22CE — This study is designed to assess the efficacy and safety of induction therapy with MK-3475 and ASG-22CE and radiation therapy with MK-3475 in patients with cT2-4aN0M0 muscle invasive bladder cancer who are unfit for or refuse radical cystectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage MIBC, N0M0
first confirmed diagnosis of MIBC... Has clinically non-metastatic bladder cancer (N0M0) determined by imaging
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic/local radiation therapy
Exception: Prior treatment for NMIBC with intravesical instillation therapy such as BCG or intravesical chemotherapy is permitted, but must be completed ≥28 days before the first dose of the trial drug.
Has received prior pelvic/local radiation therapy or any antineoplastic treatment for MIBC
Cannot have received: antineoplastic treatment for MIBC
Exception: Prior treatment for NMIBC with intravesical instillation therapy such as BCG or intravesical chemotherapy is permitted, but must be completed ≥28 days before the first dose of the trial drug. Prior systemic treatment received for treatment of NMIBC is not permitted.
Has received prior pelvic/local radiation therapy or any antineoplastic treatment for MIBC
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-PD-L2 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: checkpoint inhibitor
agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Cannot have received: antibody-drug conjugate (ASG-22CE, other MMAE-containing ADCs)
Has received prior therapy with an ASG-22CE or other MMAE-containing ADCs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify